Your Web Site
News source: Business Wire CombinatoRx, Incorporated today provided a detailed review of selected therapeutic programs and a general company update at its annual Research and Development (R&D) day at its corporate headquarters in Cambridge, MA. Presentation highlights included: -- Phase 2b clinical data for Synavive(TM) (CRx-102) in osteoarthritis is on track for release in October 2008 -- Fundamental new understanding of mechanism of action for Synavive(TM), with publication expected later in 2008 -- Successful aligned release formulation for Synavive(TM) -- Progress updates on other clinical stage programs including CRx-401 in diabetes and CRx-191 and CRx-197 in topical dermatology -- New data on emerging programs in B-cell malignancies and Hepatitis C -- New research information in rare disease franchise and... [read full story]
